Neuraxis inc NRXS.US Overview Analysis
)NRXS AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
NRXS Current Performance
3.81%
Neuraxis inc
1.31%
Avg of Sector
0.58%
S&P500
Top 10 High Relevance to NRXS
- NNOX Nano-x imaging ltdValue 3Trend 3Swing Trading 4Whale Interest 1Dividend 1See more
NRXS Profile
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company's second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient's ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.